同源康

ABOUT

TYK Medicines Focus on new drug research and development
Together, we search for the cure.

Discover More

NEWS

NMPA Approval: Asandeutertinib for First Line Treatment of EGFR Mutant Lung Cancer with Brain Metastases

ASCO 2026 LBA | 95.5% iORR, Asandeutertinib Sets New Benchmark in First-line Treatment for EGFR-mutated NSCLC Brain Metastases

ASCO 2026 Preview: LBA Oral Abstract Session-Landmark Results from the Pivotal Study of Asandeutertinib vs. Osimertinib as First-Line Treatment for EGFR-Mutated NSCLC with Brain Metastases

RESEARCH

An innovative biotechnology company focusing on the research and development of innovative drugs